OneSource Specialty Pharma Ltd

OneSource Specialty Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, as recent indicator signals suggest a complex outlook for the pharmaceutical small-cap. Despite a modest daily decline of 1.19%, the stock’s technical parameters reveal mixed signals that warrant close attention from investors navigating the Pharmaceuticals & Biotechnology sector.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, signalling a transition from a sideways trend to a mildly bearish outlook. Recent technical indicators, including MACD, RSI, and moving averages, suggest increasing pressure on the stock, which has underperformed the broader market benchmarks over multiple time frames.

OneSource Specialty Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis below reflects the stock's current position as of 23 August 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s technical indicators present a nuanced picture that investors should carefully analyse amid broader market pressures.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators reveal a complex picture of bearish signals on weekly charts contrasted by mildly bullish daily moving averages, signalling a period of consolidation and uncertainty for investors.

OneSource Specialty Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and financial performance despite ongoing challenges in management efficiency and valuation metrics.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a shift in price momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a nuanced interplay of technical indicators, including MACD, RSI, moving averages, and other momentum oscillators, signalling a cautious but positive outlook for investors.

OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of indicator signals. Despite a modest intraday decline, the stock’s technical profile reveals a nuanced picture that investors in the Pharmaceuticals & Biotechnology sector should carefully analyse.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, signalling a transition from a sideways trend to a mildly bullish momentum. Despite this, the stock’s overall technical grade has been downgraded to Sell, reflecting a complex interplay of indicator signals and price action that investors should carefully analyse.

OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish stance to a sideways trend. This change comes amid a sharp price decline and deteriorating market sentiment, raising concerns for investors in the Pharmaceuticals & Biotechnology sector.

OneSource Specialty Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with the latest insights into the company’s performance and outlook.

OneSource Specialty Pharma Ltd has recently shifted from a sideways technical trend to a mildly bullish stance, reflecting a nuanced change in price momentum. Despite a modest day change of -0.02%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse amid broader market conditions.

OneSource Specialty Pharma Ltd. posted a consolidated net profit of ₹25.00 crores in Q1 FY27, marking a dramatic turnaround from the ₹0.19 crore loss in Q1 FY26, though the stock has struggled to maintain momentum, declining 16.07% over the past year. The ₹18,862 crore market capitalisation pharmaceutical company delivered sequential growth of 443.48% in net profit compared to Q4 FY26's ₹4.60 crores, whilst revenue expanded 37.20% year-on-year to ₹449.02 crores.

OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of indicator signals. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s price action and technical indicators suggest a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

OneSource Specialty Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and financial trends despite ongoing challenges in profitability and valuation. The upgrade, effective from 22 July 2026, is driven primarily by a shift in technical momentum and a stabilisation in long-term sales growth, signalling cautious optimism for investors in this small-cap pharmaceutical player.